"We demand a public apology from EMA's Christa Wirthumer-Hoche for her negative comments..., (which) raise serious questions about possible political interference in the ongoing EMA review," the developers wrote on the official Sputnik V Twitter account.
Kremlin spokesman Dmitry Peskov called Wirthumer-Hoche's statement regrettable and inappropriate.
"(A) recent study carried out by the Gamaleya Centre in Russia showed that revaccination with Sputnik V vaccine is working very well against new coronavirus mutations, including the UK and South African strains of coronavirus.
We believe that vector-based vaccines are actually better for future revaccinations than vaccines based on other platforms.
Argentina was one of the first countries in the region to sign an agreement with Russia to buy Sputnik V and has already received 1.22 million doses from the Russian Gamaleya Institute.
This potential development will be carried out with the participation of Hetero Labs Limited, a laboratory established in India, with whom Laboratorios Richmond has had a strategic alliance for more than 25 years.
Experts said the Phase III trial results meant the world had another effective weapon to fight the deadly pandemic and justified to some extent Moscow’s decision to roll out the vaccine before final data had been released.
The results were based on data from 19,866 volunteers, of whom a quarter received a placebo, the researchers, led by the Gamaleya Institute’s Denis Logunov, said in The Lancet.